|
BCX-1777 in Treating Patients With Refractory Cancer Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on BCX-1777 in Treating Patients With Refractory Cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. BCX-1777 in Treating Patients With Refractory Cancer Clinical research trials and BCX-1777 in Treating Patients With Refractory Cancer healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like BCX-1777 in Treating Patients With Refractory Cancer. BCX-1777 in Treating Patients With Refractory Cancer Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a BCX-1777 in Treating Patients With Refractory Cancer clinical trial. Human subjects often obtain the finest healthcare possible for their BCX-1777 in Treating Patients With Refractory Cancer condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "B" Clinical Trials Conditions > BCX-1777 in Treating Patients With Refractory Cancer  BCX-1777 in Treating Patients With Refractory Cancer
BCX-1777 in Treating Patients With Refractory Cancer
For Condition: female reproductive cancer,skin tumor,Gastrointestinal Cancer,hematopoietic and lymphoid cancer,central nervous system cancer
Status: Recruiting
Sponsor(s): BioCryst Pharmaceuticals ,
Synopsis: RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
Details: OBJECTIVES: Primary - Determine the maximum tolerated dose of BCX-1777 in patients with refractory T-cell or non-T-cell malignancies. - Determine the safety and dose-limiting toxicity of this drug in these patients. Secondary - Determine the pharmacokinetics of single oral and single and multiple IV doses of this drug in these patients. - Determine the oral bioavailability of this drug in these patients. - Determine, preliminarily, the antitumor activity of this drug in these patients. OUTLINE: This is an open-label, nonrandomized, dose-escalation, multicenter study. - Courses 1 and 2: Patients receive oral BCX-1777 on days 1 and 15* and BCX-1777 IV over 30 minutes on days 8* and 22*. - Beginning approximately 6 days* after the completion of courses 1 and 2, patients receive BCX-1777 IV over 30 minutes once daily on days 1-5 and 8-12 (total of 10 doses). NOTE: *+/- 1 day Patients with stable disease or better and no dose-limiting toxicity (DLT) may receive an additional 10-dose treatment course (as in course 3) after a 10- to 16-day drug-free interval. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of BCX-1777 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience DLT. Patients are followed at 14 and 30 days. PROJECTED ACCRUAL: A total of 3-24 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed diagnosis of 1 of the following: - Hematologic malignancy that is refractory to at least 1 prior curative treatment - Non-hematologic tumor that is refractory to at least 2 prior therapies, with or without measurable disease, including the following: - Gastrointestinal adenocarcinoma of 1 of the following sites: - Pancreatic - Biliary - Gastric - Colorectal - Esophageal - Melanoma - Ovarian cancer - Astrocytoma brain tumor - Not immediately eligible for any other treatment that would be potentially curative or life-prolonging, in the opinion of the investigator - Patients who may be candidates for future bone marrow transplantation are eligible - No brain metastases (other than astrocytomas) - No clinically significant pleural effusion - No complete tumor obstruction (e.g., bronchus, ureter, or bowel) PATIENT CHARACTERISTICS: Age - 18 and over Performance status - ECOG 0-2 OR - Karnofsky 50-100% Life expectancy - Not specified Hematopoietic - WBC at least 3,500/mm^3 - Absolute neutrophil count at least 1,500/mm^3 - Platelet count greater than 50,000/mm^3 - Hematocrit stable without the need for transfusion (epoetin alfa support allowed) Hepatic - Bilirubin less than 1.5 times upper limit of normal (ULN) (unless due to Gilbert's syndrome) - SGOT and SGPT less than 2 times ULN - No active hepatitis B or C Renal - Creatinine clearance at least 50 mL/min Cardiovascular - No American Heart Association class III or IV cardiac disease Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - HIV negative - No active systemic infection requiring IV antibiotics PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - Not specified Endocrine therapy - Concurrent corticosteroids allowed provided the patient is on a stable regimen Radiotherapy - Not specified Surgery - Not specified Other - Recovered from prior therapy - No grade 2-4 toxicity - More than 3 weeks since prior antineoplastic and/or investigational therapy - No other concurrent systemic antineoplastic or investigational therapy
Total Enrollment:
Location and Contact Information:
Overall Study Official:
TonyMorris, Study Chair, Pharma Research Corporation
Cleveland Clinic Taussig Cancer Center *Recruiting*
Cleveland, Ohio, 44195
United States
Recruiting Ronald Bukowski 216-444-6825
Additional Information:
Study ID Numbers: CDR0000341332; CCF-5909,BIOCRYST-1777BC-101
Study Start Date:
Record last reviewed: November 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00073944
Other Skin Tumor Studies:
1. Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract
2. Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen
3. Chemotherapy in Treating Patients With Solid Tumors
4. Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors
5. Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity
Related Studies:
Other skin tumor Clinical Trials
Other Ohio Clinical Trials
Other Cleveland Clinical Trials
BCX-1777 in Treating Patients With Refractory Cancer
|
|
|
|
|
|
|
|
